Innovative triple therapy for asthma! Novart Enerzair Breezhaler: High doses significantly reduce asthma exacerbation compared to medium doses!

08, 2020 // -- Novartis recently unveiled Enerzair Breezhaler (QVM149; indacaterol acetate/gly) at the 2020 European Respiratory Society (ERS) International Conference. After-the-fact analysis data from the cobyronium bromide/mometasone furoate, acetic aciddatero/Glon bromide/mormisone; IND/GLY/MF) Key III IRIDIUM Study (NCT02571777).
results showed that in patients treated with moderate or high doses of LABA but with uncontrolled asthma, Enerzair Breezhaler significantly reduced the exacerbation rate of moderate or severe asthma at one high dose per day compared to one medium dose per day.
post-mortem analysis also showed that the safety of high-dose Enerzair Breezhaler was consistent with previous clinical development projects in PHASE III/IIIb PLATINUM.
Enerzair Breezhaler is made up of acetic aciddatro (IND, a LABA), Glyn bromide (GLY), a long-acting toxaphene-alkali-inhibitor antagonist (LAMA), A fixed-dose combination of momisong (MF, high-dose ICS) combines the bronchial dilation of IND with GLY's anti-toxic pyridoline and high-dose ICS anti-inflammatory action.
the drug is given using a Breezhaler device with a dose confirmation mechanism, which allows daily inhalation treatment using a single inhaler.
, Enerzair Breezhaler (IND/GLY/MF) has been approved in Japan, Canada and the European Union.
, published at the conference, showed that Enerzair Breezhaler had high doses (150/50/160μg) and medium doses (1) in asthma patients who were not adequately controlled by inhalation therapy during the 52-week treatment period. Compared to 50/50/80μg, the annualized rate of moderate or severe asthma exacerbation was significantly reduced by 21% (p-0.026) and 31% (p-0.003).
addition, Enerzair Breezhaler's high dose reduced the annualized rate of all aggravations (light, medium and severe) by 14% compared to the medium dose, but this finding was not statistically significant.
both doses showed good safety and tolerance.
Kenneth Chapman, a professor of medicine at the University of Toronto, said: "This post-mortem analysis supports the potential of high doses of IND/GLY/MF as an effective enhanced treatment that can further reduce asthma exacerbation in people with runaway asthma.
these findings also complement the efficacy and safety data from a key IRIDIUM study that showed that high doses of IND/GLY/MF had the potential to improve lung function and reduce exacerbation compared to a standard care therapy, LABA/ICS.
" In early July, Enerzair Breezhaler was approved by the European Union as a maintenance therapy for adults with asthma who received a combination of long-acting beta2-receiving astrations (LABA) and high-dose inhaled corticosteroids (ICS) to maintain a condition that did not adequately control the condition and experienced one or more acute asthma exacerbations in the past year.
also approved with the drug include the first digital companion (sensors and applications) that provides inhalation confirmation, drug alerts, and access to objective data to better support treatment decisions.
It's worth noting that Enerzair Breezhaler is the first europeanly approved daily LABA/LAMA/ICS fixed-dose combination and the first asthma treatment in the European Union to be prescribed with a digital companion (Propeller Health sensors and applications customized for Breezhaler devices).
digital companion provides patients with inhalation confirmations, drug reminders, and access to objective treatment data that can be shared with doctors to help them make better treatment decisions.
In addition, the innovative asthma twin therapy Atectura Breezhaler (IND/MF, once a day) has been approved in the European Union, Japan, and Canada as a fixed dose combination of LABA/ICS as a maintenance therapy for adults aged 12 years, receiving inhaled corticosteroids (ICS) and inhaled short-acting beta agitants (SABA) that do not adequately control the condition in adults and adolescents with asthma.
is committed to bringing Enerzair Breezhaler (IND/GLY/MF) and Atectura Breezhaler (IND/MF) to patients around the world, both of which are currently under regulatory review in several countries, including Switzerland.
as Novarccer's ongoing commitment to reducing the environmental impact of its asthma portfolio, both products will be drugd through the Breezhaler® device, which does not use HFCs/CFC.
() Original origin: Novartis post hoc analysiss show high-dose Enerzair Breezhaler reduces asthmas
s medium-dose, vinting key pivotal IRIDIUM study findings.